A Study Of Oral Paricalcitol To Treat Proteinuric Renal Disease
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Diabetic Nephropathy and other proteinuric renal diseases are the major cause of kidney disease in the United States. The degree of proteinuria is associated with risk for renal disease progression and cardiovascular outcomes. Deficiency of 1-25 Vitamin D develops early in CKD, and is undertreated. Vitamin D may have important effects on factors that drive proteinuria and renal disease progression in patients with proteinuric renal diseases. Therefore, Paricalcitol treatment may reduce proteinuria and slow renal deterioration.
| Condition | Intervention |
|---|---|
|
Proteinuric Renal Disease |
Drug: paricalcitol (initial dose 1 mcg orally per day) |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Study Start Date: | July 2006 |
| Estimated Study Completion Date: | November 2007 |
Objectives:
- To determine the effect of oral paricalcitol on protein excretion in patients with proteinuric renal diseases
- To determine the effect of oral paricalcitol on renal disease progression in patients with proteinuric renal diseases Hypothesis: Oral paricalcitol will reduce protein excretion in proteinuric kidney disease Study Design: Prospective, randomized, placebo controlled, double blind, trial of paricalcitol compared to placebo.
Sample Size: 60 patients, 30 in each group Summary of Patient Eligibility Criteria: Subjects with proteinuric renal disease (>400 mg/24 hours)
Randomization and Dosage: Patients will be randomized to treatment with oral paricalcitol (initial dose 1 mcg orally per day) compared to placebo Duration : 6 Months
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Stable chronic kidney disease
- Urine protein : Creatinine ratio > 0.4
- Chronic kidney disease stage 2-4 with eGFR 15-90 ml/min
- PTH (intact) >20 pg/ml and <250 pg/ml
- Age 18-85
- If on ACEI/ARB, then dose optimized (BP, K)
Exclusion Criteria:
- Failure to provide informed consent
- Glomerunephritis requiring active treatment with immunosuppresive therapy
- Serum phosphorus > 5.2
- Serum calcium (adjusted for albumin)> 10.0
- Active malignancy
- Likelihood of requiring renal replacement therapy within 1 year
- Uncontrolled hypertension
Contacts and Locations| Contact: Steven Fishbane, MD | 516-663-2169 | sfishbane@metrorenal.com |
| United States, New York | |
| Winthrop Univ. Hospital | Recruiting |
| Mineola, New York, United States, 11501 | |
| Contact: Steven Fishbane, MD 516-663-2169 | |
| Study Chair: | Alex Schoen | Winthrop University Hospital |
More Information
No publications provided by Winthrop University Hospital
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Steven Fishbane, MD, Winthrop-University Hospital |
| ClinicalTrials.gov Identifier: | NCT00469625 History of Changes |
| Other Study ID Numbers: | Z # 13178 |
| Study First Received: | May 3, 2007 |
| Last Updated: | May 29, 2009 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Kidney Diseases Urologic Diseases |
ClinicalTrials.gov processed this record on May 22, 2013